Načítá se...

Crystal structure of dihydropyrimidine dehydrogenase, a major determinant of the pharmacokinetics of the anti-cancer drug 5-fluorouracil

Dihydropyrimidine dehydrogenase catalyzes the first step in pyrimidine degradation: the NADPH-dependent reduction of uracil and thymine to the corresponding 5,6-dihydropyrimidines. Its controlled inhibition has become an adjunct target for cancer therapy, since the enzyme is also responsible for the...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Dobritzsch, Doreen, Schneider, Gunter, Schnackerz, Klaus D., Lindqvist, Ylva
Médium: Artigo
Jazyk:Inglês
Vydáno: Oxford University Press 2001
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC145429/
https://ncbi.nlm.nih.gov/pubmed/11179210
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/emboj/20.4.650
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!